Gastric Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By End User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, Other), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.15 Billion
CAGR (2026-2031)	6.66%
Fastest Growing Segment	Chemotherapy
Largest Market	North America
Market Size (2031)	USD 6.11 Billion

Market Overview

The Global Gastric Cancer Therapy Market will grow from USD 4.15 Billion in 2025 to USD 6.11 Billion by 2031 at a 6.66% CAGR. Gastric cancer therapy encompasses a range of pharmacological and biological interventions, including chemotherapy, targeted therapeutics, and immunomodulators, designed to treat malignancies originating in the stomach lining. The market is primarily driven by the rising prevalence of gastric carcinoma due to aging global populations and shifting dietary patterns, creating an urgent demand for efficacious treatments. Furthermore, the sector is supported by an increase in regulatory approvals for novel drug formulations, which facilitates the rapid commercialization of advanced therapeutic options.

Despite these positive factors, the market faces a significant challenge in the form of the high costs associated with developing and administering complex biologic drugs, which restricts patient access in cost-sensitive healthcare regions. This financial barrier is often compounded by stringent reimbursement policies that delay the adoption of premium therapies. Highlighting the continued burden of this disease, according to the American Cancer Society, in 2025, there were an estimated 30,300 new cases of stomach cancer and 10,780 deaths attributed to the condition in the United States.

Key Market Drivers

The Global Gastric Cancer Therapy Market is experiencing a transformative phase driven by the rapid adoption of novel immunotherapy regimens, which are replacing traditional chemotherapy as the standard of care for advanced stages. Immune checkpoint inhibitors, particularly PD-1/PD-L1 antagonists, have demonstrated superior clinical outcomes, leading to their widespread integration into first-line treatment protocols. This therapeutic shift is significantly boosting market value, evidenced by the commercial success of leading biologic agents. For instance, according to Merck, February 2025, in the 'Fourth-Quarter and Full-Year 2024 Financial Results', Keytruda generated $29.5 billion in total sales for 2024, a growth trajectory partly fueled by its expanded indications in gastrointestinal malignancies. The clinical efficacy driving this adoption is further underscored by regulatory milestones; according to the FDA, March 2025, in the 'FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma' announcement, the confirmed overall response rate for the pembrolizumab combination therapy was 73%, validating its potency in improving patient outcomes.

Simultaneously, the development of advanced targeted therapeutic agents, specifically antibody-drug conjugates (ADCs) and therapies directed at biomarkers like HER2 and Claudin 18.2, is a critical growth engine. These agents offer precision treatment options that minimize systemic toxicity while maximizing tumor eradication, addressing the urgent need for personalized medicine. The market impact of these sophisticated therapies is immediate and substantial, as they capture significant revenue share upon approval. Illustrating this rapid market penetration, according to BioPharma Dive, May 2025, in the article 'At ASCO, Enhertu cements growing role in stomach cancer care', the targeted antibody-drug conjugate Enhertu amassed more than $3 billion in 2024 revenue, highlighting the lucrative potential of precision oncology assets within the gastric cancer space.

Download Free Sample Report

Key Market Challenges

The high cost associated with developing and administering complex biologic drugs constitutes a substantial impediment to the expansion of the Global Gastric Cancer Therapy Market. These advanced therapeutics often carry premium price tags that exceed the financial capabilities of healthcare systems in developing nations and strain budgets in developed economies. Consequently, patient access is severely restricted in cost-sensitive regions where the disease burden is often highest, directly limiting the volume of therapies administered and dampening overall market revenue growth.

This financial strain causes payers to enforce stringent reimbursement policies and delay the approval of coverage for novel treatments, which hampers the commercial uptake of these drugs. The escalating expense of oncology management is evident in recent industry data. According to the International Foundation of Employee Benefit Plans, in 2025, the median spend on cancer care by employers increased by 11 percent compared to the prior year. Such rising costs compel healthcare providers and insurers to prioritize less expensive alternatives over innovative biologic interventions, thereby stalling the widespread adoption of new gastric cancer therapies and reducing the potential return on investment for pharmaceutical developers.

Key Market Trends

The proliferation of bispecific antibody clinical programs is reshaping the market by enabling simultaneous targeting of distinct tumor-associated antigens or immune checkpoints. This dual-targeting mechanism addresses the limitations of monospecific antibodies, such as tumor heterogeneity and drug resistance, by enhancing binding specificity and triggering more potent immune responses. Developers are advancing assets that target combinations like HER2/HER2, PD-1/CTLA-4, and Claudin 18.2/4-1BB to improve durability in advanced gastric cancer. Validating this therapeutic potential, according to Jazz Pharmaceuticals, January 2026, in the 'Ziihera Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA' announcement, the bispecific antibody Ziihera demonstrated a median overall survival benefit of more than two years, establishing a new benchmark for efficacy in this patient population.

Simultaneously, the integration of liquid biopsy for non-invasive monitoring is expanding as a method for early detection and longitudinal disease assessment. This technology addresses the challenges of traditional tissue biopsies by analyzing circulating tumor DNA to guide treatment selection and detect recurrence earlier. The shift towards incorporating these diagnostics into large-scale clinical protocols highlights their growing utility in standardizing patient management. Illustrating this commitment to validation, according to Guardant Health, July 2025, in the 'First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test' press release, the company initiated a pivotal study aiming to enroll up to 24,000 participants to rigorously evaluate the performance of its multi-cancer detection platform in identifying malignancies including gastric cancer.

Segmental Insights

The Chemotherapy segment is currently positioning itself as the fastest-growing category within the Global Gastric Cancer Therapy Market, primarily due to its integral role in newly authorized combination regimens. This surge is driven by recent regulatory milestones, such as the U.S. Food and Drug Administration (FDA) granting approvals for immunotherapies to be administered alongside fluoropyrimidine and platinum-based chemotherapy for advanced gastric cancer. These strategic endorsements have revitalized the clinical utility of cytotoxic agents, establishing them as the essential foundation of first-line treatment. Consequently, the sustained demand for these backbone therapies in conjunction with novel agents is fueling the segment's rapid expansion.

Regional Insights

North America maintains a leading position in the Global Gastric Cancer Therapy Market due to high healthcare expenditure and the early adoption of targeted therapeutics. The region benefits from a robust clinical trial ecosystem and accelerated drug approval pathways provided by the U.S. Food and Drug Administration. Additionally, the presence of major pharmaceutical companies fosters continuous development in oncology treatments. Comprehensive reimbursement policies further improve patient access to these therapies, ensuring steady revenue growth. These structural advantages allow North America to command a significant share of the global market.

Recent Developments

• In June 2025, Amgen Inc. reported positive topline results from the Phase 3 FORTITUDE-101 clinical trial evaluating bemarituzumab. The study met its primary endpoint, showing that bemarituzumab combined with chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus chemotherapy. The trial focused on patients with first-line, FGFR2b-positive, unresectable, locally advanced, or metastatic gastric or gastroesophageal junction cancer. These findings highlighted the potential of targeting FGFR2b overexpression as a viable therapeutic strategy and underscored the company's progress in developing targeted treatments for complex gastric malignancies.
• In December 2024, BeiGene, Ltd. secured approval from the U.S. Food and Drug Administration for Tevimbra (tislelizumab-jsgr) in combination with chemotherapy for the treatment of gastric cancer. The authorization specifically covered the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. This regulatory milestone was supported by the RATIONALE-305 Phase 3 trial, where the immunotherapy combination demonstrated a statistically significant reduction in the risk of death compared to chemotherapy alone. This approval further established Tevimbra as a key therapeutic option within the competitive global landscape of gastric cancer treatments.
• In October 2024, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy. This approval authorized the regimen for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors were CLDN18.2 positive. Vyloy became the first and only CLDN18.2-targeted therapy approved in the United States for this specific patient population. The decision was based on results from the Phase 3 SPOTLIGHT and GLOW trials, which demonstrated significant improvements in progression-free and overall survival.
• In August 2024, AstraZeneca and Daiichi Sankyo received conditional approval from China's National Medical Products Administration for Enhertu (trastuzumab deruxtecan). This authorization permitted the use of the antibody-drug conjugate as a monotherapy for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who had previously undergone two or more treatment regimens. The regulatory decision was supported by positive efficacy data from the DESTINY-Gastric06 Phase II trial. This development marked a significant expansion for the therapy in China, a region that accounts for a substantial proportion of the global gastric cancer burden.

Key Market Players

• Abbott Laboratories Inc.
• Amgen, Inc.
• Celltrion Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Agilent Technologies Inc.
• AstraZeneca Plc
• Pfizer Inc.
• Eli Lilly & Co.
• GlaxoSmithKline Plc

By Therapy Type	By End User	By Region
Chemotherapy Targeted Therapy Immunotherapy Radiation Therapy Surgery	Ambulatory Surgery Centers Hospitals and Specialty Clinics Other	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Gastric Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gastric Cancer Therapy Market, By Therapy Type:

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Surgery

• Gastric Cancer Therapy Market, By End User:

• Ambulatory Surgery Centers
• Hospitals and Specialty Clinics
• Other

• Gastric Cancer Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE